{"id":"NCT00660829","sponsor":"Meda Pharmaceuticals","briefTitle":"A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","officialTitle":"Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Subjects With Seasonal Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2008-02","completion":"2008-04","firstPosted":"2008-04-17","resultsPosted":"2010-01-28","lastUpdate":"2015-04-13"},"enrollment":536,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"0.15% Azelastine Hydrochloride","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The Purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone.","primaryOutcome":{"measure":"Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) (AM and PM Combined)at 14 Days","timeFrame":"baseline and 14 days","effectByArm":[{"arm":"Placebo","deltaMin":17.98,"sd":3.334},{"arm":"Astepro 0.15%","deltaMin":18.48,"sd":3.283}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":266},"commonTop":["Dysgesusia","Nasal Discomfort","Epistaxis"]}}